Concord Biotech share price today

Concord Biotech Ltd's share price was ₹1,245.60 at the close on 30 October 2026. It has been rising for 12 weeks. That is 8.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,015 and ₹1,571, and at that close it sat 41% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Concord Biotech Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running.

Over the last 3.2 years the share price moved +32% while the NIFTY 500 moved +29%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 16 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

For July to September 2026 (the quarter ended 30 September 2026), Concord Biotech reported revenue of ₹309 crore, up 25.1% from ₹247 crore a year earlier, and a profit of ₹70.0 crore, up 11.1% from ₹63.0 crore.

Concord Biotech results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Concord Biotech's management discussed these results on a call held on 28 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Concord Biotech closed at ₹1,245.60 on 30 October 2026, down 13.7% from ₹1,443.80 a year earlier (31 October 2025) and up 3.4% over three years. Its highest weekly close since August 2023 was ₹2,601.10 on 20 September 2024.

Concord Biotech share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes.

172 weekly closes from 18 August 2023 to 30 October 2026.

4 Nov 2026: Bonus issue: 1 new share for every 1 held (ex-date). 30 Oct 2026: Concord Biotech closed at ₹1,245.60, up 1.3% on the week and down 9.4% on the month.

Earlier

• 28 Oct 2026: Concord Biotech held its results call for July to September 2026. Management guided: FY27 revenue slightly better than 18-19%, API slightly higher with Q3 visibility.
• Results for July to September 2026: Revenue up 25.1% and profit up 11.1% on a year earlier.
• 24 Jul 2026: ex-date for a dividend of ₹7.55 a share.

Concord Biotech paid ₹7.55 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.61% at the ₹1,245.60 close on 30 October 2026. The last was a dividend of ₹7.55 a share, ex-date 24 July 2026.

Concord Biotech dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Concord Biotech Ltd paid out 30% of its profit as dividends in FY26, and it paid a dividend in 6 of its last 7 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 28 October 2026, Concord Biotech's management guided: FY27 revenue slightly better than 18-19%, API slightly higher with Q3 visibility.

“I would say that we would continue to consider growth for this financial year to be slightly better than our historical growth of 18%.”Ankur Vaid, on the call for July to September 2026

What management guided

• Operating margin 38-40% over next few years once new units ramp.
• Capital spending ₹50-60 crore each in FY27-28, totalling ₹100-120 crore vs ₹20-30 crore maintenance.
• Effective tax rate 24-25% for rest of FY27 and FY28.
• Injectable topline around ₹300 crore over 3-4 years on ₹5,000 crore TAM.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 28 October 2026.

When Concord Biotech reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Injectable contracts expected in H2 - check for signed deals and Unit 4 utilisation commentary moving up from low base.

Concord Biotech is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.

Concord Biotech Ltd earned ₹70.0 Cr of net profit in the Sep 2026 quarter, +11.1% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹259 Cr. Over 6 years profit has grown 7.4% a year on average. That is 22.7% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹63.0 Cr.

For the full year, FY26 profit was ₹259 Cr (−30.4% on the year before).

Why profit moved: revenue changed +25.1% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −2.5% and revenue +10.2%. Profit is growing slower than sales: rising costs are taking part of the growth.

Concord Biotech Ltd reported ₹309 Cr of revenue in the Sep 2026 quarter, +25.1% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 6 years it has grown 12.8% a year on average. The last full year, FY26, came in at ₹1,055 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹1,170 Cr.

FY26 revenue was ₹1,055 Cr, −12.1% on the year before.

Recent pace: the last four quarters grew +10.2% on average, against 12.8% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +4.0%, against +3.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −13.3%, against −7.7% a year (rolling over).

Concord Biotech Ltd's operating margin was 34.0% in the Sep 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 7 years it has been between 35.0% and 53.0%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −2.3 percentage points on the year while gross margin changed −4.3 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 83% of Concord Biotech Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹267 Cr of operating cash against ₹259 Cr of profit. After ₹96.0 Cr of spending on assets, ₹171 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 83% of profit came in as cash: the cash cycle got 37 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 1.6× depreciation over three years. The next section checks what that spending is building.

Concord Biotech Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 493 days in FY26, up from 456 days in FY21. It spent ₹284 Cr on assets over the last 3 years. Customers take 159 days to pay, and stock sits for 485 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,055 Cr, each day of that cycle ties up about ₹2.9 Cr, so roughly ₹1,425 Cr is tied up in the business at any time.

FY26: customers took 159 days to pay and stock sat for 485 days, about 16.0 months of sales sitting as stock, for a full cycle of 493 days, longer than FY21's 456.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 485 days. Customers pay about 159 days after that. Suppliers are paid at 151 days. Together that makes the 493-day cycle.

Spending on assets: ₹284 Cr over the last 3 years, against ₹182 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹79.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Concord Biotech Ltd's P/E is 45.7×, near the low end of its own history: it has been lower only 26% of the time. Its usual P/E (the middle reading) is 51.8×, over 3.2 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹26.99.

Why the multiple is where it is: over the past year earnings per share moved −29.8% while the price moved −13.7%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 3 years the price moved +1.1% a year; about +6.3% a year came from earnings growth and about −5.2 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Concord Biotech Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −13.3% in the latest quarter, against +28.9% at its best in 12 quarters, with ROCE falling at 18.7%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Concord Biotech Ltd earned a ROCE of 17% in FY26. Its return on capital used (ROIC) is 3.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 24.5% net margin and 0.47× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 24.5% net margin × 0.47× asset turnover × 1.11× leverage (assets divided by equity) ≈ 12.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 15.8% − 12.0% = +3.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error.

Concord Biotech Ltd has total debt of ₹2.0 Cr against shareholder equity of ₹2,072 Cr as of Sep 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.02 in FY23 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Domestic institutions raised their stake in Concord Biotech Ltd by 1.1 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 10.9% of the company. Foreign institutions moved −0.8 points over the same period, to 7.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Domestic institutions: +1.1 points over 8 quarters, to 10.9%; Foreign institutions: −0.8 points over 8 quarters, to 7.3%; Promoters: +0.0 points over 8 quarters, to 44.1%.

Why the owners changed: domestic institutions drove it (+1.1 points), with the other side taken by foreign institutions (−0.8 points). They raised their stake step by step.

For Concord Biotech Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

There is no score against its industry: Concord Biotech Ltd is score temporarily unavailable, fetchAllRows(mlaSectorData.supplemental[1]): page at offset 1000 failed: canceling statement due to statement timeout for undefined.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, score temporarily unavailable, fetchAllRows(mlaSectorData.supplemental[1]): page at offset 1000 failed: canceling statement due to statement timeout.

Concord Biotech is the 15th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Cohance Lifesciences, Syngene International and Jubilant Pharmova. Just below it: Blue Jet Healthcare, Supriya Lifescience and Morepen Laboratories.

Pharma - API & CRAMS companies close in size

12. Cohance Lifesciences Ltd ₹16,999 crore
13. Syngene International Ltd ₹16,256 crore
14. Jubilant Pharmova Ltd ₹14,716 crore
15. Concord Biotech Ltd ₹13,031 crore
16. Blue Jet Healthcare Ltd ₹9,550 crore
17. Supriya Lifescience Ltd ₹6,819 crore
18. Morepen Laboratories Ltd ₹6,211 crore

All 24 Pharma - API & CRAMS companies, largest first

Companies close in size in other industries

496. Gujarat Mineral Development Corporation Ltd ₹13,090 crore · Mining/Minerals
497. Fractal Analytics Ltd ₹13,059 crore · IT Enabled Services/Business Process Outsourcing
498. Concord Biotech Ltd ₹13,031 crore
499. Anupam Rasayan India Ltd ₹13,019 crore · Speciality Chemicals
500. Godawari Power & Ispat Ltd ₹12,987 crore · Mining/Minerals - Iron Ore

Sector Alpha, written by code from the published numbers. Data as of 30 October 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.